MKI67 and neoplasm: An immunohistochemical analysis of Ki-67, a marker of cell proliferative activity, revealed that the combination of everolimus and gemcitabine decreased the percentage of Ki-67-positive tumor cells in mice more than either gemcitabine or everolimus alone (Figure 5b,c).